Dupont Capital Management’s Heron Therapeutics HRTX Stock Holding History

Dupont Capital Management’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-24,221	Closed	-$102K	–	1469
2022 Q3	$102K	Buy	+24,221	New	+$94.8K	0.01%	1028
2021 Q4	–	Sell	-21,153	Closed	-$226K	–	1766
2021 Q3	$226K	Sell	21,153 -2,990	-12%	-$36.4K	0.01%	1200
2021 Q2	$375K	Hold	24,143	–	–	0.01%	1119
2021 Q1	$391K	Sell	24,143 -4,952	-17%	-$88.3K	0.01%	1056
2020 Q4	$616K	Sell	29,095 -2,172	-7%	-$37.8K	0.01%	758
2020 Q3	$463K	Sell	31,267 -2,094	-6%	-$32.7K	0.01%	793
2020 Q2	$491K	Sell	33,361 -2,979	-8%	-$48.9K	0.01%	788
2020 Q1	$427K	Hold	36,340	–	–	0.01%	723
2019 Q4	$854K	Buy	+36,340	New	+$804K	0.02%	623

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Dupont Capital Management's HRTX Position: Q4 2022 in Review

Dupont Capital Management sold out of Heron Therapeutics (HRTX) in Q4 2022, closing a stake of 24,221 shares — an estimated $102K sold.

Dupont Capital Management first reported a position in HRTX in Q4 2019 and held it in 9 quarters. The position peaked at $854K in Q4 2019. 176 funds tracked by Wall St. Rank hold HRTX as of Q4 2022.

Dupont Capital Management reported no remaining Heron Therapeutics position as of Q4 2022 after selling out during the quarter.
Dupont Capital Management sold 24,221 Heron Therapeutics shares in Q4 2022, an estimated $102K.
Dupont Capital Management first reported a position in Heron Therapeutics in Q4 2019 and held it in 9 quarters.
Dupont Capital Management's Heron Therapeutics position peaked at $854K in Q4 2019.
176 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2022.

Based on Dupont Capital Management's 13F filing for Q4 2022, filed 26 Jan 2023.